International Journal of Cancer Care and Delivery

📣 CALLING ALL AUTHORS OF ONCOLOGY/HEMATOLOGY ❗ Submit your manuscript to be featured in the International Journal of Cancer Care and Delivery. ✏ https://lnkd.in/gQaNhd-W #CallForSubmissions #medicaljournal #medicalresearch #Oncology #Hematology #CancerResearch

"It is unclear if asynchronous learning materials versus the combination of asynchronous and synchronous education is more effective when facilitating increased adoption and quality of advanced radiation techniques in Latin America." according to a new abstract. They then evaluated the efficacy of a remote, resident-led contouring curriculum. Read about their data and results at the link below ⬇ https://lnkd.in/gkEVzPai

An abstract by Luis Enrique Banegas, MA, Gabriela I. Rebollo Becerra, BA, Erica Lubetkin, MD, MPH, Francesca M. Gany, MD, MS, and jennifer leng, MD, MPH discusses cancer inequalities. Statistics show: "Inequalities in cancer screening and survival rates are associated with race/ethnicity. For example, for colorectal cancer (CRC), compared to the general population, U.S. Latinos have lower CRC screening rates (29%), are more likely to be diagnosed with advanced CRC, and have lower survival rates, and African Americans (AAs) have the highest CRC incidence and mortality." Find more information on these details at the link here ⬇ https://lnkd.in/gyWFU8KM

Neutrophil-lymphocyte ratio (NLR) has been identified as a factor of poor prognosis in metastatic colorectal cancer (mCRC) according to a new study conducted by oncology professionals at Habib Bourguiba University Hospital in Sfax, Tunisia. Read more about their specific findings in the article linked below 👇 https://lnkd.in/gbsQbuYu

"Vancomycin is a critical antibiotic utilized in the management of severe bacterial infections, especially Staphylococcus aureus, among pediatric patients with various oncological diseases." A new study by Dr. Ghulam Razaque et. al explores the impact of pharmacist led therapeutic drug monitoring of vancomycin in these patients. Read the full study and results at the link below ⬇ https://lnkd.in/gnGGn2sp

Dr. Jason Porter, Dr. Srishti Sareen, and Dr. Jaya Adabala described their research in a recent abstract, saying: "In our comprehensive cancer center, we have observed a trend of low median progression free survival (mPFS) among African American females with Extensive-Stage Small Cell Lung Cancer (ED-SCLC) treated with combination chemoimmunotherapy." Find more information about their findings at the link below ⬇ https://lnkd.in/g2_5b_HS

"Geriatric cancer patients often have multiple underlying comorbidities and impairments in their functional and cognitive status, and cancer treatment can add a heavy physical and emotional burden." A new abstract by Dr. Nicole Frerichs and Dr. Daniel Paul explores this issue in a case discussion which can be found at the link below. ⬇ https://lnkd.in/gcW9zeAV

In a recent study, oncologists and PCPs from a large public safety-net hospital system in Houston, TX were surveyed regarding the shared care of patients with cancer and chronic medical conditions. The majority reported moderate levels of interprofessional collaboration and felt that existing processes to facilitate coordination of care and comorbidity management were inadequate. The study was conducted by Dr. Kristen Simmons, Dr. Aparna Jotwani, Dr. Colbert Parker, Dr. Lee Lu, Dr. Martha Mims, Dr. Hoda Badr, and Ellen Xiang. Take a look at the data they collected at the link below ⬇ https://lnkd.in/gv7yMKfH

"Despite recent advances, socioeconomic disparities in lymphoma outcomes persist, and there is a shortage of real-world data on outcomes of underserved patients." The abstract below includes information from a retrospective cohort study conducted by examining data from patients diagnosed with lymphoma between January 2011 and June 2022 at Harris Health, Houston, TX. https://lnkd.in/gfjNg8TF Study by: Dr. Chijioke Nze MD, MPH, Dr. Jun Y Jiang, Dr. Danielle Guffey, Dr. Rockbum Kim, Dr. Abi O., Dr. Omar Rosales, Dr. Raka Bandyo, Dr. Courtney Miller-Chism, Dr. Mark Udden, Dr. Martha Mims, Dr. Hilary Ma, Dr. Gustavo A. Rivero, Dr. Akiva Diamond, Dr. Purnima S. Teegavarapu, Dr. Ang Li, and Dr. Christopher R. Flowers, MD

"The failure rates and recurrence rates of Head and Neck Cancers (HNCs) in India are soaring, which is a challenge, with patients being unaffordable to the newer treatments of full-dose checkpoint inhibitors," according to an abstract by Dr Satheesh Chiradoni Thungappa. However, the addition of low-dose immunotherapy to chemotherapy could change outcomes for this staggering number of patients with further research needed to confirm the treatment's efficacy. Read more here ⬇ https://lnkd.in/gmHxC7EG